Australia's CSL profit falls 7 percent on weak plasma sales as buyback lifts to 750 million dollars
CSL reported a seven percent profit drop today amid weak plasma sales and policy shifts in the US and China. The company raised its buyback to $750 million.
洞察:
CSL Limited , the biotechnology firm based in Australia 
AU, reported a 7 percent decline in its first-half underlying net profit after tax on a constant currency basis, which fell to $1.92 billion for the six months ended December 31. In conjunction with the earnings release, the company announced it has increased its share buyback program to $750 million. This material capital return decision is expected to influence the company’s financial position and shareholder returns following the reduced revenue and profit recorded in its core plasma business.
AU, reported a 7 percent decline in its first-half underlying net profit after tax on a constant currency basis, which fell to $1.92 billion for the six months ended December 31. In conjunction with the earnings release, the company announced it has increased its share buyback program to $750 million. This material capital return decision is expected to influence the company’s financial position and shareholder returns following the reduced revenue and profit recorded in its core plasma business.The decline in financial performance was driven by several internal and external factors, including weaker sales in the plasma-therapy sector and a drop in albumin sales. Additionally, the company’s bottom line was affected by restructuring and impairment charges incurred during the half-year period. These results reflect the current operating environment for CSL’s primary divisions, including CSL Behring and Seqirus, as they navigate shifting market dynamics.
